ストックスクリーナーアプリを入手
16.49
0.06%
-0.01
前日終値:
$16.50
開ける：
$16.515
24時間の取引高:
59,087
Relative Volume:
0.96
時価総額：
$894.30M
収益：
-
当期純損益:
$-143.59M
株価収益率:
-5.8401
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
-4.52%
1か月 パフォーマンス:
-13.76%
6か月 パフォーマンス:
-7.31%
1年 パフォーマンス:
-40.70%
1日の値動き範囲:
$16.06
$17.01
1週間の範囲:
$16.06
$17.57
52週間の値動き範囲:
$15.21
$28.84
Pharvaris Nv Stock (PHVS) Company Profile
PHVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
16.49 | 894.30M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-25 | 開始されました | Wedbush | Outperform |
| 2023-08-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 開始されました | Bryan Garnier | Buy |
| 2022-09-13 | 再開されました | JMP Securities | Mkt Outperform |
| 2022-08-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-02 | 開始されました | BofA Securities | Neutral |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Pharvaris Nv (PHVS) 最新ニュース
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Where are the Opportunities in (PHVS) - Stock Traders Daily
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris: Despite 30% Decline, Still Fair At Best (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest - MarketBeat
Trend Tracker for (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS) - MarketBeat
Learn to Evaluate (PHVS) using the Charts - Stock Traders Daily
Pharvaris (PHVS) Price Target Increased by 38.65% to 32.93 - MSN
Pharvaris price target lowered to $46 from $50 at JMP Securities - Yahoo Finance
Long Term Trading Analysis for (PHVS) - Stock Traders Daily
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
PHVS Makes Notable Cross Below Critical Moving Average - Nasdaq
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan
Pharvaris Nv (PHVS) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):